Sunitinib News and Research

RSS
Sunitinib malate is approved by the Food and Drug Administration (FDA) to treat a type of stomach cancer called gastrointestinal stromal tumor (GIST). It is used in patients whose condition has become worse while taking another drug called imatinib mesylate or who are not able to take imatinib mesylate.
Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

FDA approves combination immunotherapy for treatment of kidney cancer

FDA approves combination immunotherapy for treatment of kidney cancer

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Oncolytic virus alerts the immune system to attack tumors

Oncolytic virus alerts the immune system to attack tumors

New organ-on-a-chip technology provides simple setting to study blood vessel formation

New organ-on-a-chip technology provides simple setting to study blood vessel formation

Novel drug shows promise in treating metastatic kidney cancer

Novel drug shows promise in treating metastatic kidney cancer

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Combination immunotherapy shows better overall survival in kidney cancer patients

Combination immunotherapy shows better overall survival in kidney cancer patients

Experimental drug outperforms standard first-line therapy for advanced kidney cancer patients

Experimental drug outperforms standard first-line therapy for advanced kidney cancer patients

HIF-2 inhibitors could be promising target to combat kidney cancer

HIF-2 inhibitors could be promising target to combat kidney cancer

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Popular kidney cancer drugs do not reduce incidence of recurrence

Popular kidney cancer drugs do not reduce incidence of recurrence

Therapy change significantly improves treatment outcomes for renal cell carcinoma patients

Therapy change significantly improves treatment outcomes for renal cell carcinoma patients

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity